AC Immune SA
ACIUDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
ACI-35.030
Alzheimer's Disease
ACI-24.060 at Dose A
Amyloid Plaque
ACI-7104.056 at Dose A
Parkinson Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ACI-35.030 | Phase 2 | Alzheimer's Disease | - | - |
ACI-24.060 at Dose A | Phase 2 | Amyloid Plaque | - | - |
ACI-7104.056 at Dose A | Phase 2 | Parkinson Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in AC Immune SA's drug pipeline?→
CatalystAlert tracks 3 drug candidates in AC Immune SA's (ACIU) pipeline across Phase 2. Its lead program is ACI-35.030 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AC Immune SA's next FDA catalyst?→
AC Immune SA's (ACIU) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ACIU biotech catalysts?→
Add ACIU to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AC Immune SA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.